Literature DB >> 34344408

Growth hormone treatment for adults with Prader-Willi syndrome: another point of view.

Harry J Hirsch1, Varda Gross-Tsur2,3.   

Abstract

Growth hormone treatment for children with Prader Willi syndrome (PWS) has shown proven benefits not only in increasing final height but also with positive effects on body composition and motor development. In a recent letter to the editor, Hoybye and colleagues recommend growth hormone treatment for adults with PWS based exclusively on the genetic diagnosis and without regard for growth hormone secretory status. We question whether the benefits of growth hormone treatment in PWS adults, mainly improvement in body composition, are significant enough to justify the as yet unkown consequences of long-term treatment in an adult population. Morbidity and mortality in PWS are mainly due to complications of obesity, and growth hormone treatment does not result in a decrease in BMI or waist circumference. Increases in insulin-like factor-1 as a result of growth hormone treatment over the course of several decades in PWS adults raises concern over possible increase risk of cancer. Compliance with daily injections is likely to be poor. We suggest that efforts to provide appropriate dietary and exercise regimens may be more beneficial and cost-effective than advocating for growth hormone treatment for adults with PWS.
© 2021. The Author(s).

Entities:  

Keywords:  Growth hormone; Insulin-like growth factor-1; Obesity; Prader-Willi syndrome

Year:  2021        PMID: 34344408     DOI: 10.1186/s13023-021-01952-9

Source DB:  PubMed          Journal:  Orphanet J Rare Dis        ISSN: 1750-1172            Impact factor:   4.123


  17 in total

1.  Visceral adipose tissue resides within the reference range in children with Prader-Willi syndrome receiving nutritional intervention on a regular basis.

Authors:  Mikiko Koizumi; Shinobu Ida; Yasuko Shoji; Yukiko Nishimoto; Yuri Etani; Masanobu Kawai
Journal:  Endocr J       Date:  2020-06-19       Impact factor: 2.349

2.  Non-Alcoholic Fatty Liver Disease (NAFLD) in children and adolescents with Prader-Willi Syndrome (PWS).

Authors:  D Fintini; E Inzaghi; M Colajacomo; S Bocchini; G Grugni; C Brufani; M Cappa; V Nobili; S Cianfarani; A Crinò
Journal:  Pediatr Obes       Date:  2015-07-01       Impact factor: 4.000

Review 3.  Understanding the growth hormone therapy adherence paradigm: a systematic review.

Authors:  Benjamin G Fisher; Carlo L Acerini
Journal:  Horm Res Paediatr       Date:  2013-04-30       Impact factor: 2.852

Review 4.  THERAPY OF ENDOCRINE DISEASE: Testosterone supplementation and body composition: results from a meta-analysis study.

Authors:  Giovanni Corona; Vito A Giagulli; Elisa Maseroli; Linda Vignozzi; Antonio Aversa; Michael Zitzmann; Farid Saad; Edoardo Mannucci; Mario Maggi
Journal:  Eur J Endocrinol       Date:  2015-11-04       Impact factor: 6.664

5.  Sexual dichotomy of gonadal function in Prader-Willi syndrome from early infancy through the fourth decade.

Authors:  H J Hirsch; T Eldar-Geva; F Bennaroch; Y Pollak; V Gross-Tsur
Journal:  Hum Reprod       Date:  2015-09-06       Impact factor: 6.918

6.  Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey.

Authors:  Merlin G Butler; Ann M Manzardo; Janalee Heinemann; Carolyn Loker; James Loker
Journal:  Genet Med       Date:  2016-11-17       Impact factor: 8.822

7.  Glucagon stimulation test to assess growth hormone status in Prader-Willi syndrome.

Authors:  L Casamitjana; O Giménez-Palop; R Corripio; R Pareja; E Berlanga; M Rigla; J C Oliva; A Caixàs
Journal:  J Endocrinol Invest       Date:  2020-07-27       Impact factor: 4.256

8.  The genetic background and vitamin D supplementation can affect irisin levels in Prader-Willi syndrome.

Authors:  M F Faienza; G Brunetti; G Grugni; D Fintini; A Convertino; P Pignataro; A Crinò; S Colucci; M Grano
Journal:  J Endocrinol Invest       Date:  2021-03-03       Impact factor: 5.467

9.  Irisin and the Metabolic Phenotype of Adults with Prader-Willi Syndrome.

Authors:  Harry J Hirsch; Itai Gross; Yehuda Pollak; Talia Eldar-Geva; Varda Gross-Tsur
Journal:  PLoS One       Date:  2015-09-03       Impact factor: 3.240

10.  Is non-alcoholic fatty liver disease less frequent among women with Prader-Willi syndrome?

Authors:  Giorgio Bedogni; Graziano Grugni; Valerio Nobili; Fiorenza Agosti; Antonella Saezza; Alessandro Sartorio
Journal:  Obes Facts       Date:  2014-02-22       Impact factor: 3.942

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.